Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset

BACKGROUND: In the global, Phase 3, ASCEND-5 study, ceritinib improved progression-free survival (PFS) vs chemotherapy in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) who had previously progressed on crizotinib and platinum-based chemotherapy. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiura, Katsuyuki, Imamura, Fumio, Kagamu, Hiroshi, Matsumoto, Shingo, Hida, Toyoaki, Nakagawa, Kazuhiko, Satouchi, Miyako, Okamoto, Isamu, Takenoyama, Mitsuhiro, Fujisaka, Yasuhito, Kurata, Takayasu, Ito, Masayuki, Tokushige, Kota, Hatano, Ben, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892855/
https://www.ncbi.nlm.nih.gov/pubmed/29474558
http://dx.doi.org/10.1093/jjco/hyy016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892855/
https://www.ncbi.nlm.nih.gov/pubmed/29474558
http://dx.doi.org/10.1093/jjco/hyy016

Ejemplares similares